Mental Health DailyResearch. Evidence. Perspective.Published research on alpha-synuclein.
A 2026 mouse study found that complete IL-6 deficiency worsened motor dysfunction and dopaminergic injury in MPTP and alpha-synuclein A53T Parkinson’s disease models, with earlier and broade…
Read articleA human, mouse, and zebrafish study linked long-term chlorpyrifos exposure to Parkinson’s disease risk, with the strongest exposure-duration estimate reaching OR 2.74 for workplace proximity…
Read articleA 2026 Parkinsonism study involving 63 male rats found that Antrodia cinnamomea plus citrate-stabilized silver nanoparticles reduced 6-OHDA motor, oxidative-stress, inflammatory, α-synuclein…
Read articleA 2026 PPMI analysis found that Parkinson’s patients with positive CSF α-synuclein seed amplification assay results kept gaining levodopa benefit over follow-up, while SAA-negative patients …
Read articleParkinson’s disease has a years-to-decades prodromal stage where motor symptoms haven’t yet emerged but pathology is accumulating. A 2026 review by Schaeffer et al. synthesizes the case for …
Read articleMultiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-dr…
Read article
